These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16262203)

  • 1. [How safe are ADHD drugs?].
    Schwarz R; Muskalla B
    Kinderkrankenschwester; 2005 Oct; 24(10):437. PubMed ID: 16262203
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focalin XR for ADHD.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):22-4. PubMed ID: 19305368
    [No Abstract]   [Full Text] [Related]  

  • 4. Cotempla XR-ODT--another long-acting methylphenidate for ADHD.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):183-185. PubMed ID: 29125594
    [No Abstract]   [Full Text] [Related]  

  • 5. Safe and effective methylphenidate therapy in a pediatric patient with glaucoma.
    Lewis H; Lewis J
    Atten Defic Hyperact Disord; 2012 Mar; 4(1):37-9. PubMed ID: 22311620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Priapism - side effect of methylphenidate].
    Aktuelle Urol; 2014 Mar; 45(2):94. PubMed ID: 24700059
    [No Abstract]   [Full Text] [Related]  

  • 7. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
    Janols LO; Liliemark J; Klintberg K; von Knorring AL
    Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quillivant XR--an extended release oral suspension of methylphenidate.
    Med Lett Drugs Ther; 2013 Feb; 55(1409):10-1. PubMed ID: 23381227
    [No Abstract]   [Full Text] [Related]  

  • 9. Increase in Menstrual Cycle Length Induced by Extended-Release Methylphenidate in an Adolescent with Attention-Deficit/Hyperactivity Disorder.
    Mutlu C; Bahalı K; Gunes H; Adaletli H
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):860-861. PubMed ID: 26397126
    [No Abstract]   [Full Text] [Related]  

  • 10. Jornay PM -- evening-dosed methylphenidate for ADHD.
    Med Lett Drugs Ther; 2019 Aug; 61(1578):126-128. PubMed ID: 31386648
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacology of adult ADHD with stimulants.
    Spencer TJ
    CNS Spectr; 2007 Apr; 12(4 Suppl 6):8-11. PubMed ID: 17715564
    [No Abstract]   [Full Text] [Related]  

  • 12. Trichotillomania in Attention-Deficit/Hyperactivity Disorder Under Methylphenidate Treatment.
    Kara T; Akaltun İ
    J Clin Psychopharmacol; 2017 Aug; 37(4):484. PubMed ID: 28492426
    [No Abstract]   [Full Text] [Related]  

  • 13. OROS methylphenidate-induced skin eruptions.
    Coskun M; Tutkunkardas MD; Zoroglu S
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):593-4. PubMed ID: 19877987
    [No Abstract]   [Full Text] [Related]  

  • 14. [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2006 Nov; 29(11):415-6. PubMed ID: 17131689
    [No Abstract]   [Full Text] [Related]  

  • 15. Status epilepticus associated with the administration of long-acting methylphenidate in a 7-year-old girl.
    Goetz M; Surman CB; Mlynarova E; Krsek P
    J Clin Psychopharmacol; 2012 Apr; 32(2):300-2. PubMed ID: 22388167
    [No Abstract]   [Full Text] [Related]  

  • 16. Transdermal methylphenidate (Daytrana) for ADHD.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
    [No Abstract]   [Full Text] [Related]  

  • 17. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
    McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of stimulant medications for ADHD.
    Natl Bur Econ Res Bull Aging Health; 2014; (1):1-2. PubMed ID: 25141389
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.
    Lurie S; O'Quinn A
    J Neuropsychiatry Clin Neurosci; 1991; 3(1):41-50. PubMed ID: 7580171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.
    Park-Wyllie L; van Stralen J; Castillon G; Sherman SE; Almagor D
    Clin Ther; 2017 Oct; 39(10):2006-2023. PubMed ID: 28988700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.